Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies

References

• World Health Organization. Noncommunicable diseases country profiles 2011. WHO report. Geneva, Switzerland: WHO Press, World Health Organization, 2011. http://whqlibdoc.who.int/publications/2011/9789241502283_eng.pdf. Accessed March 2013
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:387-96
   PubMed Web of Science ®Google Scholar
• Bjork S. The cost of diabetes and diabetes care. Diab Res Clin Pract 2001;54:S13-18
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M; CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002;45:S1-4
   Google Scholar
• Killilea T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care 2002;8(16 Suppl):S441-9
   PubMed Web of Science ®Google Scholar
• Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm 2006;12:130-42
   PubMed Web of Science ®Google Scholar
• Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45:S13-17
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Foundation clinical practice guideline. Brussels, Belgium: International Diabetes Foundation, 2012. http://www.idf.org/guidelines. Accessed March 2013
   Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Gudbjörnsdottir S, Cederholm J, Nilsson PM, et al; Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003;26:1270-6
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation--European Region and the Federation of European Nurses in Diabetes. Diabetes. The policy puzzle: is Europe making progress? Brussels, Belgium: The International Diabetes Federation Europe and Federation of European Nurses in Diabetes, 2008. http://ec.europa.eu/health/major_chronic_diseases/docs/policy_puzzle_2008.pdf. Accessed March 2013
   Google Scholar
• IDF Diabetes Atlas, 4th ed. Brussels, Belgium: The International Diabetes Federation, 2009. http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance. Accessed March 2013
   Google Scholar
• Leese B. Economic evaluations of type II diabetes. Pharmacoeconomics 1995;8(1 Suppl):23-7
   Google Scholar
• Ettaro L, Songer TJ, Zhang P, et al. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004;22:149-64
   PubMed Web of Science ®Google Scholar
• Liebl A, Breitscheidel L, Nicolay C, et al. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008;24:2349-58
   PubMed Web of Science ®Google Scholar
• Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700
   PubMed Web of Science ®Google Scholar
• Costi M, Dilla T, Reviriego J, et al. Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. Acta Diabetol 2010;47(1 Suppl):169-75
   Google Scholar
• Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 2011;27:887-95
   PubMed Web of Science ®Google Scholar
• Jones S, Castell C, Goday A, et al. Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study. Clinicoecon Outcomes Res 2012;4:383-93
   PubMedGoogle Scholar
• Oguz A, Benroubi M, Brismar K, et al. Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in 5 countries: results from the TREAT Study. Curr Med Res Opin 2013: published online 9 May 2013, doi: 10.1185/03007995.2013.803053
   Google Scholar
• Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther 2012;3:9
   PubMedGoogle Scholar
• Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003;9:309-16
   PubMedGoogle Scholar
• Smith HT, Liebl A, Jones S, et al. Cost and resource use following insulin initiation in Europe: 24 month follow up data from the INSTIGATE study. Vienna, Austria: EASD, 2009. Diabetologia
   Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9
   PubMed Web of Science ®Google Scholar
• Doničová V, Brož J, Sorin I. Health care provision for people with diabetes and postgraduate training of diabetes specialists in eastern European countries. J Diabetes Sci Technol 2011;5:1124-36
   Google Scholar
• Liebl A, Breitscheidel L, Benter U, et al. Start der Insulintherapie bei Typ-2-Diabetes: 1-Jahres-Daten der INSTIGATE-Studie [Initiation of Insulin Therapy in Type 2 Diabetics: One-Year Results from the INSTIGATE Study (German 12-month data)]. Diabetes, Stoffwechsel und Herz 2012;21:13-19
   Google Scholar